Home Cart Sign in  
Chemical Structure| 22232-54-8 Chemical Structure| 22232-54-8

Structure of Carbimazole
CAS No.: 22232-54-8

Chemical Structure| 22232-54-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Carbimazole is a carbethoxy derivative of methimazole used to treat hyperthyroidism.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Carbimazole

CAS No. :22232-54-8
Formula : C7H10N2O2S
M.W : 186.23
SMILES Code : O=C(N1C=CN(C)C1=S)OCC
MDL No. :MFCD00027421
InChI Key :CFOYWRHIYXMDOT-UHFFFAOYSA-N
Pubchem ID :31072

Safety of Carbimazole

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Description
Carbimazole is an orally administered antithyroid medication, is swiftly transformed into Methimazole post-absorption. It inhibits the thyroid peroxidase enzyme from iodinating and coupling tyrosine residues on thyroglobulin, subsequently reducing thyroxine production. Moreover, Carbimazole exhibits anti-inflammatory and neuroprotective properties, making it relevant for both hyperthyroidism treatment and neurological research[1].[2].[3].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00430547 Graves' Ophthalmopathy Not Applicable Completed - Australia, Victoria ... More >> Barwon Health - The Geelong Hospital Geelong, Victoria, Australia, 3220 Less <<
NCT03064542 - Recruiting June 1, 2019 Singapore ... More >> Tan Tock Seng Hospital, Endocrinology Clinic Recruiting Singapore, Singapore, 308433 Contact: Melvin Leow, MD    6407 0105    melvin_leow@sics.a-star.edu.sg    Contact: Yanrong Guo, Msc    83444898    yanrong_GUO@ttsh.com.sg Less <<
NCT01436994 Paediatric Thyrotoxicosis Phase 3 Completed - United Kingdom ... More >> Royal Aberdeen Children's Hospital Aberdeen, United Kingdom Birmingham Children's Hospital Birmingham, United Kingdom Addebrookes Hospital Cambridge, United Kingdom Wales College of Medicine Cardiff, United Kingdom University Hospital Coventry, United Kingdom Ninewells Hospital Dundee, United Kingdom Royal Hospital for Sick Children Edinburgh, United Kingdom Royal Hospital for Sick Children Glasgow, United Kingdom Hereford Hospital Hereford, United Kingdom Crosshouse Hospital Kilmarnock, United Kingdom Alder Hey Children's Hospital Liverpool, United Kingdom St Bart's Hospital London, United Kingdom St George's Hospital London, United Kingdom Royal Manchester Children's Hospital Manchester, United Kingdom Royal Victoria Infirmary Newcastle upon Tyne, United Kingdom Norfolk & Norwich University Hospitals Norwich, United Kingdom Oxford Radcliffe Hospitals Oxford, United Kingdom Sheffield Children's Hospital Sheffield, United Kingdom Less <<
NCT03303053 Hyperthyroidism ... More >> Graves Disease Less << Phase 3 Recruiting March 1, 2018 Malaysia ... More >> Hospital Queen Elizabeth 2 Recruiting Kota Kinabalu, Sabah, Malaysia, 88300 Contact: Yin Khet Fung, Dr.    +6 088324600    fung@doctors.org.uk    Contact: Gayathri D Krishnan, Dr.    +6 088324600    kgaya3@yahoo.com    Sub-Investigator: Pei Lin Chan, Dr.          Hospital Ampang Recruiting Ampang, Selangor, Malaysia, 68000 Contact: Vijiya M Valayatham, Dr    +60342896000    ammu_vj@yahoo.com    Hospital Putrajaya Recruiting Putrajaya, Wilayah Persekutuan, Malaysia, 62250 Contact: Serena SK Khoo, Dr.    +6 03 83124200    sk_liv@rocketmail.com    Contact: Zanariah Hussein, Dr.    +6 03 83124200    zanariahh@hotmail.com    Sub-Investigator: Siti A Alias, Dr          Sub-Investigator: Lisa Mohamed Nor, Dr          Sub-Investigator: Rashidah Bahari, Dr          Sub-Investigator: Nurul Z Badarudin, Dr Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.37mL

1.07mL

0.54mL

26.85mL

5.37mL

2.68mL

53.70mL

10.74mL

5.37mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories